OBJECTIVES: To describe the onset, progression, and remission of symptomatic androgen deficiency (SAD) using longitudinal data from the Massachusetts Male Aging Study (MMAS). DESIGN: A prospective, population-based study of men living in Boston, Massachusetts. Data were collected in three waves: T1 (1987/89), T2 (1995/97), T3 (2002/04). Onset, progression, and remission were defined in terms of transitions in SAD status from one wave to the next. SETTING: In-person, in-home interviews. PARTICIPANTS: Seven hundred sixty-six community-dwelling men aged 40 to 70 at baseline (T1) contributed data from T1 to T2 and 391 from T2 to T3. MEASUREMENTS: SAD was defined in terms of serum total and free testosterone (T) levels and symptoms associated with low circulating androgens. Total T and sex hormone-binding globulin (SHBG) were measured using radioimmunoassay. Free T was calculated from total T and SHBG measurements. RESULTS: At T2 or T3, the likelihood of SAD was markedly greater for subjects who had exhibited SAD at the previous wave (odds ratio=3.8, 95% confidence interval=1.9-7.4), overall 55% of subjects who exhibited SAD experienced remission by the next study wave. The probability of SAD was greater with older age and greater body mass index. Multivariate models demonstrated that the likelihood of remission was at least 50% for most subpopulations. CONCLUSION: Over approximately 15 years of follow-up, SAD did not represent a stable health state. The likelihood of SAD would remit exceeded the likelihood that it would not, particularly among younger and leaner men.
OBJECTIVES: To describe the onset, progression, and remission of symptomatic androgen deficiency (SAD) using longitudinal data from the Massachusetts Male Aging Study (MMAS). DESIGN: A prospective, population-based study of men living in Boston, Massachusetts. Data were collected in three waves: T1 (1987/89), T2 (1995/97), T3 (2002/04). Onset, progression, and remission were defined in terms of transitions in SAD status from one wave to the next. SETTING: In-person, in-home interviews. PARTICIPANTS: Seven hundred sixty-six community-dwelling men aged 40 to 70 at baseline (T1) contributed data from T1 to T2 and 391 from T2 to T3. MEASUREMENTS: SAD was defined in terms of serum total and free testosterone (T) levels and symptoms associated with low circulating androgens. Total T and sex hormone-binding globulin (SHBG) were measured using radioimmunoassay. Free T was calculated from total T and SHBG measurements. RESULTS: At T2 or T3, the likelihood of SAD was markedly greater for subjects who had exhibited SAD at the previous wave (odds ratio=3.8, 95% confidence interval=1.9-7.4), overall 55% of subjects who exhibited SAD experienced remission by the next study wave. The probability of SAD was greater with older age and greater body mass index. Multivariate models demonstrated that the likelihood of remission was at least 50% for most subpopulations. CONCLUSION: Over approximately 15 years of follow-up, SAD did not represent a stable health state. The likelihood of SAD would remit exceeded the likelihood that it would not, particularly among younger and leaner men.
Authors: Thomas G Travison; Andre B Araujo; Varant Kupelian; Amy B O'Donnell; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2006-12-05 Impact factor: 5.958
Authors: D J Brambilla; S M McKinlay; J B McKinlay; S R Weiss; C B Johannes; S L Crawford; C Longcope Journal: J Clin Epidemiol Date: 1996-03 Impact factor: 6.437
Authors: Andre B Araujo; Gretchen R Esche; Varant Kupelian; Amy B O'Donnell; Thomas G Travison; Rachel E Williams; Richard V Clark; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2007-08-14 Impact factor: 5.958
Authors: A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann Journal: Osteoporos Int Date: 2014-05-07 Impact factor: 4.507